APOBEC3B and neoplasm: Inhibiting APOBEC3B via modified single-stranded DNA and thereby reducing the risk of genomic mutations (43–45) and targeting uracil DNA glycosylases to selectively inhibit tumor cells with high APOBEC3B expression (46) have been described as possible strategies.